bp0089 rrid ab 1107769 Search Results


igg2a isotype control  (Bio X Cell)
98
Bio X Cell igg2a isotype control
EZH2 inhibition alone and combined with immunotherapy is effective at controlling tumor burden in mouse models of LSCC. A, Representative MRI scans of autochthonous mice from each treatment arm at baseline and after treatment. B, Waterfall plot showing change in tumor volume for each mouse on all treatment arms, ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test on log 2 -transformed values. C, H&E and HALO nuclear phenotyper images showing the cells within an autochthonous Lkb1/Pten tumor and a syngeneic graft seeded from Lkb1/Pten tumoroids. D, Percentage tumor growth from the syngeneic mouse model during 14 days of indicated treatments. ***, P = 0.0004; ****, P < 0.0001 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test, *, P = 0.024 by two-tailed t test on log 2 -transformed values, Mice/tumors n are placebo = 4/8, EPZ6438 = 5/9, anti-PD1 = 6/8, combo = 5/9, mean ± SEM. is plotted. E, Flow cytometry analysis of dissociated tumors from the syngeneic grafts from the indicated treatment arms at day 14. Percentage of EpCAM+ cells expressing IA/IE or PD-L1 are graphed, mean ± SEM is plotted, placebo n = 7, EZH2 inhibitor n = 7, anti-PD1 n = 8, combo n = 7 with two experimental replicates each, *, P = 0.035; ***, P = 0.0008 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test. F, From the same tumor grafts, MFI for HLA-A in the EpCAM+ cells was graphed, mean ± SEM is plotted, placebo n = 7, EZH2 inhibitor n = 7, anti-PD1 n = 8, combo n = 7 with 2 experimental replicates each, **, P = 0.0015 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test. G, From tumor grafts, PD1+/CD3+/CD4+ cells and PD1+/CD3+/CD8+ were gated and percentage of cells bound to <t>Rat-IgG2A</t> antibody are graphed, mean ± SEM is plotted, placebo n = 6, EZH2 inhibitor n = 6, anti-PD1 n = 7, combo n = 7; **, P < 0.006; ***, P = 0.0001; ****, P < 0.0001 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test. H, From the grafts, percentage of CD3+/SSC-low cells within the CD45+ fraction and percentage of CD8+ cells within the CD3+ fraction were graphed, please see for representative gates, placebo n = 8, EZH2 inhibitor n = 8, anti-PD1 n = 9, combo n = 7 with two experimental replicates each, *, P = 0.0197; ****, P < 0.0001 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test. See also .
Igg2a Isotype Control, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bp0089+rrid+ab+1107769/InVivoMAb+rat+IgG2a+isotype+control%2C+anti-trinitrophenol/pmc10863487-38-10-13
Average 98 stars, based on 1 article reviews
igg2a isotype control - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier
bp0089 rrid ab 1107769 rat igg1 bio x cell  (Bio X Cell)
96
Bio X Cell bp0089 rrid ab 1107769 rat igg1 bio x cell
Figure 3. CD137 promotes Tex cell expansion and differentiation (A–D) Naive WT mice were treated with anti-CD137 (3H3, 10 mg) or <t>IgG</t> control mAbs. (A) Experimental design. (B–D) FACS plot and graphs showing Ki-67 expression by the indicated CD8+ T cell subsets along treatment.
Bp0089 Rrid Ab 1107769 Rat Igg1 Bio X Cell, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bp0089+rrid+ab+1107769/InVivoPlus+rat+IgG2a+isotype+control%2C+anti-trinitrophenol/pm37392737-231-176-181
Average 96 stars, based on 1 article reviews
bp0089 rrid ab 1107769 rat igg1 bio x cell - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
be0089 rrid ab 1107769 invivoplus polyclonal syrian hamster igg bio x cell  (Bio X Cell)
94
Bio X Cell be0089 rrid ab 1107769 invivoplus polyclonal syrian hamster igg bio x cell
Figure 3. CD137 promotes Tex cell expansion and differentiation (A–D) Naive WT mice were treated with anti-CD137 (3H3, 10 mg) or <t>IgG</t> control mAbs. (A) Experimental design. (B–D) FACS plot and graphs showing Ki-67 expression by the indicated CD8+ T cell subsets along treatment.
Be0089 Rrid Ab 1107769 Invivoplus Polyclonal Syrian Hamster Igg Bio X Cell, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bp0089+rrid+ab+1107769/InVivoPlus+polyclonal+Syrian+hamster+IgG/pm37625401-632-115-122
Average 94 stars, based on 1 article reviews
be0089 rrid ab 1107769 invivoplus polyclonal syrian hamster igg bio x cell - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
anti keyhole limpet hemocyanin  (Bio X Cell)
97
Bio X Cell anti keyhole limpet hemocyanin
Figure 3. CD137 promotes Tex cell expansion and differentiation (A–D) Naive WT mice were treated with anti-CD137 (3H3, 10 mg) or <t>IgG</t> control mAbs. (A) Experimental design. (B–D) FACS plot and graphs showing Ki-67 expression by the indicated CD8+ T cell subsets along treatment.
Anti Keyhole Limpet Hemocyanin, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bp0089+rrid+ab+1107769/InVivoMAb+rat+IgG2b+isotype+control%2C+anti-keyhole+limpet+hemocyanin/pm40343794-233-243-248
Average 97 stars, based on 1 article reviews
anti keyhole limpet hemocyanin - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
invivomab anti mouse gm csf  (Bio X Cell)
94
Bio X Cell invivomab anti mouse gm csf
Figure 3. CD137 promotes Tex cell expansion and differentiation (A–D) Naive WT mice were treated with anti-CD137 (3H3, 10 mg) or <t>IgG</t> control mAbs. (A) Experimental design. (B–D) FACS plot and graphs showing Ki-67 expression by the indicated CD8+ T cell subsets along treatment.
Invivomab Anti Mouse Gm Csf, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bp0089+rrid+ab+1107769/InVivoMAb+anti-mouse+GM-CSF/pm40343794-233-216-221
Average 94 stars, based on 1 article reviews
invivomab anti mouse gm csf - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

Image Search Results


EZH2 inhibition alone and combined with immunotherapy is effective at controlling tumor burden in mouse models of LSCC. A, Representative MRI scans of autochthonous mice from each treatment arm at baseline and after treatment. B, Waterfall plot showing change in tumor volume for each mouse on all treatment arms, ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test on log 2 -transformed values. C, H&E and HALO nuclear phenotyper images showing the cells within an autochthonous Lkb1/Pten tumor and a syngeneic graft seeded from Lkb1/Pten tumoroids. D, Percentage tumor growth from the syngeneic mouse model during 14 days of indicated treatments. ***, P = 0.0004; ****, P < 0.0001 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test, *, P = 0.024 by two-tailed t test on log 2 -transformed values, Mice/tumors n are placebo = 4/8, EPZ6438 = 5/9, anti-PD1 = 6/8, combo = 5/9, mean ± SEM. is plotted. E, Flow cytometry analysis of dissociated tumors from the syngeneic grafts from the indicated treatment arms at day 14. Percentage of EpCAM+ cells expressing IA/IE or PD-L1 are graphed, mean ± SEM is plotted, placebo n = 7, EZH2 inhibitor n = 7, anti-PD1 n = 8, combo n = 7 with two experimental replicates each, *, P = 0.035; ***, P = 0.0008 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test. F, From the same tumor grafts, MFI for HLA-A in the EpCAM+ cells was graphed, mean ± SEM is plotted, placebo n = 7, EZH2 inhibitor n = 7, anti-PD1 n = 8, combo n = 7 with 2 experimental replicates each, **, P = 0.0015 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test. G, From tumor grafts, PD1+/CD3+/CD4+ cells and PD1+/CD3+/CD8+ were gated and percentage of cells bound to Rat-IgG2A antibody are graphed, mean ± SEM is plotted, placebo n = 6, EZH2 inhibitor n = 6, anti-PD1 n = 7, combo n = 7; **, P < 0.006; ***, P = 0.0001; ****, P < 0.0001 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test. H, From the grafts, percentage of CD3+/SSC-low cells within the CD45+ fraction and percentage of CD8+ cells within the CD3+ fraction were graphed, please see for representative gates, placebo n = 8, EZH2 inhibitor n = 8, anti-PD1 n = 9, combo n = 7 with two experimental replicates each, *, P = 0.0197; ****, P < 0.0001 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test. See also .

Journal: Cancer Research Communications

Article Title: EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

doi: 10.1158/2767-9764.CRC-23-0399

Figure Lengend Snippet: EZH2 inhibition alone and combined with immunotherapy is effective at controlling tumor burden in mouse models of LSCC. A, Representative MRI scans of autochthonous mice from each treatment arm at baseline and after treatment. B, Waterfall plot showing change in tumor volume for each mouse on all treatment arms, ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test on log 2 -transformed values. C, H&E and HALO nuclear phenotyper images showing the cells within an autochthonous Lkb1/Pten tumor and a syngeneic graft seeded from Lkb1/Pten tumoroids. D, Percentage tumor growth from the syngeneic mouse model during 14 days of indicated treatments. ***, P = 0.0004; ****, P < 0.0001 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test, *, P = 0.024 by two-tailed t test on log 2 -transformed values, Mice/tumors n are placebo = 4/8, EPZ6438 = 5/9, anti-PD1 = 6/8, combo = 5/9, mean ± SEM. is plotted. E, Flow cytometry analysis of dissociated tumors from the syngeneic grafts from the indicated treatment arms at day 14. Percentage of EpCAM+ cells expressing IA/IE or PD-L1 are graphed, mean ± SEM is plotted, placebo n = 7, EZH2 inhibitor n = 7, anti-PD1 n = 8, combo n = 7 with two experimental replicates each, *, P = 0.035; ***, P = 0.0008 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test. F, From the same tumor grafts, MFI for HLA-A in the EpCAM+ cells was graphed, mean ± SEM is plotted, placebo n = 7, EZH2 inhibitor n = 7, anti-PD1 n = 8, combo n = 7 with 2 experimental replicates each, **, P = 0.0015 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test. G, From tumor grafts, PD1+/CD3+/CD4+ cells and PD1+/CD3+/CD8+ were gated and percentage of cells bound to Rat-IgG2A antibody are graphed, mean ± SEM is plotted, placebo n = 6, EZH2 inhibitor n = 6, anti-PD1 n = 7, combo n = 7; **, P < 0.006; ***, P = 0.0001; ****, P < 0.0001 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test. H, From the grafts, percentage of CD3+/SSC-low cells within the CD45+ fraction and percentage of CD8+ cells within the CD3+ fraction were graphed, please see for representative gates, placebo n = 8, EZH2 inhibitor n = 8, anti-PD1 n = 9, combo n = 7 with two experimental replicates each, *, P = 0.0197; ****, P < 0.0001 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test. See also .

Article Snippet: Anti-PD1 clone RMP1–14 (BioXCell #BP0146, RRID:AB_10949053 or #BE0146, RRID:AB_10949053) and IgG2a isotype control (BioXCell #BP0089m, RRID:AB_1107769) were diluted with InVivoPure pH 7.0 dilution buffer (BioXCell #IP0070) or InVivoPure pH 6.5 dilution buffer (BioXCell # IP0065) to a concentration of 1.25 μg/μL.

Techniques: Inhibition, Transformation Assay, Two Tailed Test, Flow Cytometry, Expressing

Figure 3. CD137 promotes Tex cell expansion and differentiation (A–D) Naive WT mice were treated with anti-CD137 (3H3, 10 mg) or IgG control mAbs. (A) Experimental design. (B–D) FACS plot and graphs showing Ki-67 expression by the indicated CD8+ T cell subsets along treatment.

Journal: Immunity

Article Title: TCR-independent CD137 (4-1BB) signaling promotes CD8 + -exhausted T cell proliferation and terminal differentiation.

doi: 10.1016/j.immuni.2023.06.007

Figure Lengend Snippet: Figure 3. CD137 promotes Tex cell expansion and differentiation (A–D) Naive WT mice were treated with anti-CD137 (3H3, 10 mg) or IgG control mAbs. (A) Experimental design. (B–D) FACS plot and graphs showing Ki-67 expression by the indicated CD8+ T cell subsets along treatment.

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Anti-mouse CD45.1- FITC (A20) BD Biosciences Cat#: 110706 RRID: AB_313495 Anti-mouse TCRb-Perc PCy5.5 (H57-597) BioLegend Cat#:109228 RRID: AB_1575173 Anti-mouse CD155 (PVR) PE (TX56) BioLegend Cat#:131508 RRID: AB_1279107 Anti-mouse TIGIT-PeCy7 (1G9) BioLegend Cat#:142108 RRID: AB_2565649 Anti-mouse TIGIT-APC (1G9) BioLegend Cat#: 142105; RRID: AB_10962572 Anti-mouse Eomes-efluor660 (DAN11MAC) Thermo Fisher Scientific Cat#:50-4875-80 RRID: AB_2574227 Anti-mouse Ki67-AF700 (SOLA15) Thermo Fisher Scientific Cat#:56-5698-92 RRID: AB_2637480 Anti-mouse Eomes-EF450 (DAN11MAC) Thermo Fisher Scientific Cat#:48-4875-82 RRID: AB_2574062 Anti-mouse IFNg BV421 (XMG1.2) BD Biosciences Cat#: 505830 RRID: AB_2563105 Anti-mouse CD226-BV421 (TX42.1) BioLegend Cat#:133615 RRID: AB_2715977 Anti-mouse TCRb-BV510 (H57-597) Biolegend Cat#:109233 RRID: AB_2562349 Anti-mouse TCRb-PercPCy5.5 (H57-597) BioLegend Cat#:109228 RRID: AB_1575173 Anti-mouse CD62L-APC (MEL-14) invitrogen Cat#: 17-0621-81 RRID: AB_469410 Anti-mouse PD1 (CD279)-BV785 (29F.1A12) BioLegend Cat#:135225 RRID: AB_2563680 Anti-mouse PD-1 Bio X Cell Cat#: BP0146 RRID: AB_10949053 Anti-mouse OX40 Bio X Cell Cat#: BE0031 RRID: AB_1107592 Anti-mouse 4-1BB (CD137, 3H3) Bio X Cell Cat#: BE0239 RRID: AB_2687721 Anti-mouse 4-1BB (CD137, LOB12.3) Bio X Cell Cat#: BE0239 RRID: AB_10949016 Anti-mouse GITR Bio X Cell Cat#: BE0063 RRID: AB_1107688 Rat IgG2a Bio X Cell Cat#: BP0089 RRID: AB_1107769 Rat IgG1 Bio X Cell Cat#: BP0169 RRID: AB_1107775 Chemicals, peptides, and recombinant proteins Recombinant murine IL-7 Peprotech Cat#: 217-17 Brefeldin A Solution (1000X) Thermo Fisher Scientific Cat#: 00-4506-51 Golgi Plug BD Biosciences Cat#: 555029 Protein Transport Inhibitor BD Biosciences Cat#: 554724 Ionomycin Sigma-Aldrich Cat#: I0634 Phorboll 12-myristate 13-acetate (PMA) Sigma-Aldrich Cat#: P8139 RPMI Medium 1640 Thermo Fisher Scientific Cat#: 61870-010 Fetal Bovine Serum N/A N/A Ficoll Paque Plus Sigma-Aldrich Cat#: 17-1440-03 Acridine Orange / Propidium Iodide (AO/PI) Logos Biosystems Cat#: F23001 (Continued on next page) e2 Immunity 56, 1631–1648.e1–e10, July 11, 2023

Techniques: Control, Expressing

Figure 5. T cell-intrinsic CD137-induced canonical NF-kB signaling drives T cell exhaustion (A–D) Cd4creCd137fl/flROSA26tomato (tomato+) and Cd137fl/flROSA26tomato (tomato) mixed BM chimeras were treated with anti-CD137 (10 mg; 3H3, i.p. twice a week) or IgG control mAbs. (A) Experimental design. (B) Ratio of tomato and tomato+ among splenic CD8+ T cells. (C) Frequency and absolute number of CD8+

Journal: Immunity

Article Title: TCR-independent CD137 (4-1BB) signaling promotes CD8 + -exhausted T cell proliferation and terminal differentiation.

doi: 10.1016/j.immuni.2023.06.007

Figure Lengend Snippet: Figure 5. T cell-intrinsic CD137-induced canonical NF-kB signaling drives T cell exhaustion (A–D) Cd4creCd137fl/flROSA26tomato (tomato+) and Cd137fl/flROSA26tomato (tomato) mixed BM chimeras were treated with anti-CD137 (10 mg; 3H3, i.p. twice a week) or IgG control mAbs. (A) Experimental design. (B) Ratio of tomato and tomato+ among splenic CD8+ T cells. (C) Frequency and absolute number of CD8+

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Anti-mouse CD45.1- FITC (A20) BD Biosciences Cat#: 110706 RRID: AB_313495 Anti-mouse TCRb-Perc PCy5.5 (H57-597) BioLegend Cat#:109228 RRID: AB_1575173 Anti-mouse CD155 (PVR) PE (TX56) BioLegend Cat#:131508 RRID: AB_1279107 Anti-mouse TIGIT-PeCy7 (1G9) BioLegend Cat#:142108 RRID: AB_2565649 Anti-mouse TIGIT-APC (1G9) BioLegend Cat#: 142105; RRID: AB_10962572 Anti-mouse Eomes-efluor660 (DAN11MAC) Thermo Fisher Scientific Cat#:50-4875-80 RRID: AB_2574227 Anti-mouse Ki67-AF700 (SOLA15) Thermo Fisher Scientific Cat#:56-5698-92 RRID: AB_2637480 Anti-mouse Eomes-EF450 (DAN11MAC) Thermo Fisher Scientific Cat#:48-4875-82 RRID: AB_2574062 Anti-mouse IFNg BV421 (XMG1.2) BD Biosciences Cat#: 505830 RRID: AB_2563105 Anti-mouse CD226-BV421 (TX42.1) BioLegend Cat#:133615 RRID: AB_2715977 Anti-mouse TCRb-BV510 (H57-597) Biolegend Cat#:109233 RRID: AB_2562349 Anti-mouse TCRb-PercPCy5.5 (H57-597) BioLegend Cat#:109228 RRID: AB_1575173 Anti-mouse CD62L-APC (MEL-14) invitrogen Cat#: 17-0621-81 RRID: AB_469410 Anti-mouse PD1 (CD279)-BV785 (29F.1A12) BioLegend Cat#:135225 RRID: AB_2563680 Anti-mouse PD-1 Bio X Cell Cat#: BP0146 RRID: AB_10949053 Anti-mouse OX40 Bio X Cell Cat#: BE0031 RRID: AB_1107592 Anti-mouse 4-1BB (CD137, 3H3) Bio X Cell Cat#: BE0239 RRID: AB_2687721 Anti-mouse 4-1BB (CD137, LOB12.3) Bio X Cell Cat#: BE0239 RRID: AB_10949016 Anti-mouse GITR Bio X Cell Cat#: BE0063 RRID: AB_1107688 Rat IgG2a Bio X Cell Cat#: BP0089 RRID: AB_1107769 Rat IgG1 Bio X Cell Cat#: BP0169 RRID: AB_1107775 Chemicals, peptides, and recombinant proteins Recombinant murine IL-7 Peprotech Cat#: 217-17 Brefeldin A Solution (1000X) Thermo Fisher Scientific Cat#: 00-4506-51 Golgi Plug BD Biosciences Cat#: 555029 Protein Transport Inhibitor BD Biosciences Cat#: 554724 Ionomycin Sigma-Aldrich Cat#: I0634 Phorboll 12-myristate 13-acetate (PMA) Sigma-Aldrich Cat#: P8139 RPMI Medium 1640 Thermo Fisher Scientific Cat#: 61870-010 Fetal Bovine Serum N/A N/A Ficoll Paque Plus Sigma-Aldrich Cat#: 17-1440-03 Acridine Orange / Propidium Iodide (AO/PI) Logos Biosystems Cat#: F23001 (Continued on next page) e2 Immunity 56, 1631–1648.e1–e10, July 11, 2023

Techniques: Control